Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panoramic: chemoradiotherapy with or without panitumumab for unresectable esophageal carcinoma
2010-019595-79Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab in esophageal cancer, Esophageal Squamous Cell Carcinoma (ESCC) and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: One-year overall survival. Started Apr 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
esophageal cancerEsophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2010-019595-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019595-79.